AU2009220462A1 - CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same - Google Patents

CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same Download PDF

Info

Publication number
AU2009220462A1
AU2009220462A1 AU2009220462A AU2009220462A AU2009220462A1 AU 2009220462 A1 AU2009220462 A1 AU 2009220462A1 AU 2009220462 A AU2009220462 A AU 2009220462A AU 2009220462 A AU2009220462 A AU 2009220462A AU 2009220462 A1 AU2009220462 A1 AU 2009220462A1
Authority
AU
Australia
Prior art keywords
alkyl
group
phenyl
hydrogen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009220462A
Other languages
English (en)
Inventor
Rahul Rajan Gandhi
Julie M. Strizki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2009220462A1 publication Critical patent/AU2009220462A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: SCHERING CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AU2009220462A 2008-02-29 2009-02-24 CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same Abandoned AU2009220462A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3253908P 2008-02-29 2008-02-29
US61/032,539 2008-02-29
PCT/US2009/034990 WO2009111218A2 (en) 2008-02-29 2009-02-24 Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same

Publications (1)

Publication Number Publication Date
AU2009220462A1 true AU2009220462A1 (en) 2009-09-11

Family

ID=40627290

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009220462A Abandoned AU2009220462A1 (en) 2008-02-29 2009-02-24 CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same

Country Status (6)

Country Link
US (1) US20110059154A1 (https=)
EP (1) EP2259772A2 (https=)
JP (1) JP2011513317A (https=)
AU (1) AU2009220462A1 (https=)
CA (1) CA2716838C (https=)
WO (1) WO2009111218A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
DE102012209008B4 (de) 2012-05-29 2015-02-05 Wellcomet Gmbh Vorrichtung zum Erzeugen von Behandlungswellen
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
CN104997725B (zh) * 2015-07-13 2017-10-20 山西锦波生物医药股份有限公司 抗hiv病毒的马来酸b07凝胶制剂配方及制备方法
EP3370701A1 (en) 2015-11-06 2018-09-12 INEB-Instituto Nacional De Engenharia Biomédica A composition for use in a method for prevention or treatment of human immunodeficiency virus infections
JP7512010B2 (ja) * 2018-09-20 2024-07-08 株式会社ヤクルト本社 経皮吸収用組成物及び経皮吸収性向上方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
KR100439357B1 (ko) * 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
SK287418B6 (sk) * 1999-05-04 2010-09-07 Schering Corporation Farmaceutický prípravok s obsahom CCR5 antagonistov a súprava s obsahom tohto prípravku
CN100355753C (zh) * 2000-05-26 2007-12-19 辉瑞大药厂 用于制备具有治疗作用的莨菪烷衍生物的中间体
AR033452A1 (es) * 2001-03-29 2003-12-17 Schering Corp Antagonistas de ccr5 utiles para el tratamiento del sida
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
JP2008526862A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション ピペラジン化合物の薬学的な塩の調製
WO2007033208A2 (en) * 2005-09-12 2007-03-22 University Of Maryland Biotechnology Institute Off. Of Research Admin/Tech. Dev. Use of indirubin and its derivatives in the treatments of hiv infection and heart failure
EP1948103A2 (en) * 2005-09-15 2008-07-30 UMD, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV

Also Published As

Publication number Publication date
CA2716838A1 (en) 2009-09-11
CA2716838C (en) 2014-01-07
WO2009111218A2 (en) 2009-09-11
EP2259772A2 (en) 2010-12-15
US20110059154A1 (en) 2011-03-10
JP2011513317A (ja) 2011-04-28
WO2009111218A3 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
US12268723B2 (en) Peptidomimetics for the treatment of coronavirus and picorna virus infections
JP7691494B2 (ja) 架橋三環式カルバモイルピリドン化合物及びその使用
CN107428693B (zh) 用于hiv治疗的异喹啉化合物
CA2716838C (en) Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
CN107207498B (zh) 用于治疗hiv的稠合嘧啶化合物
AU2023266279B2 (en) Tetracyclic compounds for treating HIV infection
CN117285513A (zh) Hiv衣壳抑制剂的胆碱盐形式
JP2007332141A (ja) 薬
HUP0202734A2 (hu) Pegilezett alfa-interferon és egy CCR5 antagonista kombinációjának alkalmazása HIV-terápiára
JP2020521739A (ja) 併用療法
TW200534854A (en) Methods of treating HIV infection
KR102879944B1 (ko) Hiv 예방용 인테그라제 억제제
US10407438B2 (en) Crystalline forms of darunavir
JP6370887B2 (ja) オンデマンド避妊のための医薬組成物およびその使用、ならびにこの医薬組成物の適用体制
TWI921385B (zh) 橋接三環胺甲醯基吡啶酮化合物及其用途
US20260083767A1 (en) Solid dosage form of a small molecule antiviral and uses thereof
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
HK1246776B (zh) 用於hiv治疗的异喹啉化合物
HK1241364A1 (en) Quinazoline derivatives used to treat hiv
HK1244276B (zh) 用於治疗hiv的稠合嘧啶化合物
MX2008007042A (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application